Antibody drug conjugates (ADCs) consist of a desirable monoclonal antibody, a highly potent cytotoxic payload and an appropriate linker. As an innovative therapeutic approach for targeted oncology treatments, ADC has emerged as a very powerful anticancer therapy with more than eight drugs approved by the FDA.
ADC linkers play key roles in determining the pharmacokinetic properties, therapeutic index and the overall success of the ADC. A well-designed linker helps the antibody to selectively deliver the cytotoxic drug to tumor cells and accurately releases the cytotoxic drug at tumor sites. In addition to conjugation, the linkers play critical roles in an ADCs’ stability during preparation, storage and systemic circulation. Two kinds of ADC linkers are used in current ADC drugs: cleavable linkers and non-cleavable linkers
BroadPharm offers a broad range of ADC linkers and payload to further empower pharmaceutical ADC drug discovery & development.
Featured products: PEG peptide, Val-Cit, Val-Cit-PAB, Val-Cit-PAB-PNP, PEG linkers, DBCO, BCN, Azide, Tetrazine, TCO, MMAE, DM1, DM4 and other payload.
BroadPharm also offers customer-oriented ADC linker synthesis and services to our customers worldwide.